Biotech

Breaking news and analysis on the biotech industry — covering drug development, clinical trials, IPOs, M&A, and the companies pushing biopharma forward.

Stock market IPO share price
Biotech

Rezera revs up for $181M IPO to fund NLRP3 inhibitor ph. 3 trial

Rezera—the new name for NodThera—is aiming for a $181 million IPO to take its NLRP3 inhibitor into phase 3 trials for a cardiovascular disease.
James Waldron Nov 5, 2026 10:15am
obesity overweight weight loss weigh

MetaVia’s GLP-1 sheds liver fat and body weight in phase 1

Nov 5, 2026 9:52am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
MA
Favicon Fierce Pharma

AZ’s reported $10B offer for Rhythm fuels talks of a bidding war

Nov 5, 2026 9:36am
video
Connected clinical research from fragmentation to progress

Connected clinical research: from fragmentation to progress

Brought to you by Medrio
Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks

Agios shedding 100 R&D roles ahead of hoped-for SCD approval

Nov 5, 2026 8:40am